A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

被引：0

作者：

Kosei Kimura

Mitsuhiko Iwamoto

Satoru Tanaka

Daigo Yamamoto

Katsuhide Yoshidome

Hiroyuki Ogura

Risa Terasawa

Nobuki Matsunami

Yuko Takahashi

Toshikatsu Nitta

Takashi Morimoto

Hiroya Fujioka

Kanako Kawaguchi

Kazuhisa Uchiyama

机构：

[1] Osaka Medical College Hospital,Department of Breast and Endocrine Surgery

[2] National Hospital Organization Osaka Minami Medical Center,Department of Breast Surgery

[3] Kansai Medical University Medical Center,Department of Breast Surgery

[4] Osaka Police Hospital,Department of Breast and Endocrine Surgery

[5] Hamamatsu University School of Medicine,Department of Breast Surgery

[6] Osaka Rosai Hospital,Department of Breast Surgery

[7] Hirakata City Hospital,Department of Breast and Endocrine Surgery

[8] Medico Shunju Shiroyama Hospital Breast Center,Division of Surgery

[9] Yao Municipal Hospital,Department of Breast Surgery

来源：

Cancer Chemotherapy and Pharmacology | 2018年 / 81卷

关键词：

Eribulin; Metastatic breast cancer; First or second-line; Objective response rate; QOL;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：923 / 933

页数：10

共 50 条

[31] Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
Nancy U. Lin
Leroy M. Parker
Steven E. Come
Harold J. Burstein
Margaret Haldoupis
Nicole Ryabin
Rebecca Gelman
Eric P. Winer
Lawrence N. Shulman
Investigational New Drugs, 2007, 25 : 369 - 375
[32] Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
Jiang, Hanfang
Li, Huiping
Song, Guohong
Di, Lijun
Shao, Bin
Yan, Ying
Liu, Xiaoran
Chen, Yifei
Zhang, Ruyan
Ran, Ran
Liu, Yaxin
Gui, Xinyu
Wang, Nan
Wang, Huan
BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 67 - 79
[33] Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
Kikawa, Yuichiro
Kotake, Takeshi
Tsuyuki, Shigeru
Kang, Yookija
Takahara, Sachiko
Fujimoto, Yuri
Yamashiro, Hiroyasu
Yoshibayashi, Hiroshi
Takada, Masahiro
Yasuoka, Rie
Nakatsukasa, Katsuhiko
Yamagami, Kazuhiko
Suwa, Hirofumi
Okuno, Toshitaka
Nakayama, Ichiro
Kato, Tatsushi
Ogura, Nobuko
Moriguchi, Yoshio
Ishiguro, Hiroshi
Kagimura, Tatsuo
Taguchi, Tetsuya
Sugie, Tomoharu
Toi, Masakazu
BREAST CANCER, 2022, 29 (05) : 796 - 807
[34] Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
Yuichiro Kikawa
Takeshi Kotake
Shigeru Tsuyuki
Yookija Kang
Sachiko Takahara
Yuri Fujimoto
Hiroyasu Yamashiro
Hiroshi Yoshibayashi
Masahiro Takada
Rie Yasuoka
Katsuhiko Nakatsukasa
Kazuhiko Yamagami
Hirofumi Suwa
Toshitaka Okuno
Ichiro Nakayama
Tatsushi Kato
Nobuko Ogura
Yoshio Moriguchi
Hiroshi Ishiguro
Tatsuo Kagimura
Tetsuya Taguchi
Tomoharu Sugie
Masakazu Toi
Breast Cancer, 2022, 29 : 796 - 807
[35] Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
Hanfang Jiang
Huiping Li
Guohong Song
Lijun Di
Bin Shao
Ying Yan
Xiaoran Liu
Yifei Chen
Ruyan Zhang
Ran Ran
Yaxin Liu
Xinyu Gui
Nan Wang
Huan Wang
Breast Cancer Research and Treatment, 2023, 199 : 67 - 79
[36] Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Kim, Ji-Yeon
Park, Seri
Im, Seock-Ah
Kim, Sung-Bae
Sohn, Joohyuk
Lee, Keun Seok
Chae, Yee Soo
Lee, Ki Hyeong
Kim, Jee Hyun
Im, Young-Hyuck
Kim, Tae-Yong
Lee, Kyung-Hun
Ahn, Jin-Hee
Kim, Gun Min
Park, In Hae
Lee, Soo Jung
Han, Hye Sook
Kim, Se Hyun
Jung, Kyung Hae
Park, Yeon Hee
CANCER COMMUNICATIONS, 2019, 39
[37] Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
Lin, Nancy U.
Parker, Leroy M.
Come, Steven E.
Burstein, Harold J.
Haldoupis, Margaret
Ryabin, Nicole
Gelman, Rebecca
Winer, Eric P.
Shulman, Lawrence N.
INVESTIGATIONAL NEW DRUGS, 2007, 25 (04) : 369 - 375
[38] Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
Sakaguchi, Koichi
Nakatsukasa, Katsuhiko
Koyama, Hiroshi
Kato, Makoto
Sakuyama, Akira
Matsuda, Takayuki
Tsunoda, Nobuyuki
Fujiwara, Ikuya
Yamaguchi, Masahide
Tanaka, Hiroki
Onishi, Kazuyoshi
Onishi, Mie
Yoshino, Yuji
Kikuchi, Takashi
Taguchi, Tetsuya
ANTICANCER RESEARCH, 2018, 38 (07) : 4073 - 4081
[39] High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)
Manso Sanchez, L.
Moreno Anton, F.
Izarzugaza Peron, Y.
Delgado Mingorance, I.
Borrega Garcia, P.
Echarri Gonzalez, M. J.
Martinez Janez, N.
Lopez Gonzalez, A.
Olier Garate, C.
Ballesteros Garcia, A.
Chacon Lopez-Muniz, I.
Ciruelos Gil, E. M.
Garcia Saenz, J. A.
Paz-Ares Rodriguez, L.
CANCER RESEARCH, 2017, 77
[40] Eribulin versus S-1 as fi rst or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a noninferiority, randomised, controlled, open-label, phase 3 trial
Takahashi, Masato
Kikawa, Yuichiro
Kashiwabara, Kosuke
Taira, Naruto
Iwatani, Tsuguo
Shimozuma, Kojiro
Ohtani, Shoichiro
Yoshinami, Tetsuhiro
Watanabe, Junichiro
Kashiwaba, Masahiro
Watanabe, Ken-ichi
Kitada, Masahiro
Sakaguchi, Koichi
Tanabe, Yuko
Aihara, Tomohiko
Mukai, Hirofumi
ECLINICALMEDICINE, 2024, 74

← 1 2 3 4 5 →